enGene Holdings

ENGN

Biotechnology · Healthcare

Price

$1.82

-0.10 (-5.21%)

Market Cap

$93.2M

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+223.3% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 15.8M (2021) → 51.1M (2025)

enGene Holdings is a small biotechnology company focused on developing gene therapy treatments for bladder cancer. It uses a technology platform called D-Linux to deliver genetic material directly into cells lining the bladder, without needing to alter the patient's DNA permanently. The company's main customers would be cancer patients and the hospitals or clinics that treat them.

enGene makes no revenue yet, which is typical for early-stage biotech companies that are still running clinical trials. It operates primarily in North America and is a very small company with a market cap around $100 million. Its main competitive edge is its proprietary D-Linux delivery platform, which it claims can target bladder tissue more precisely than older methods. The biggest risk the company faces is clinical and financial — it must prove its treatments work in trials while continuing to spend cash it does not yet earn back, meaning it may need to raise more money from investors to survive.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+8.3% YoY

YoY Growth Rate

Slow EPS growth

R&D Spend

$94M/ year

↑ Rising (+147% vs prior year)

R&D investment increasing — building for the future

Insider Activity

58.0%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~4 months

$37M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

enGene Holdings has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-10.1%

Weak — -10.1% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.10

Conservative — low debt load (0.10)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial